Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.
about
Highlight: BRCA1 and BRCA2 proteins in breast cancerMolecular tumor profiling: translating genomic insights into clinical advancesCpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian originHeterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesCpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients.Hereditary breast cancer: clinical, pathological and molecular characteristics.Identification and characterization of a transcriptional silencer upstream of the human BRCA2 geneTranslational application of epigenetic alterations: ovarian cancer as a model.Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapyImplication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphismEpigenetic targeting in breast cancer: therapeutic impact and future direction.Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoterClinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significanceCritical molecular abnormalities in high-grade serous carcinoma of the ovary.RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.Therapeutic potential of PARP inhibitors for metastatic breast cancer.CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.Isolation and initial characterization of the BRCA2 promoter.Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue.Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.The Preventive Intervention of Hereditary Breast Cancer.Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer.
P2860
Q24307401-1DD7B62F-E091-42E8-B708-349B4A788326Q24797250-12F4E9FC-6B1C-40CA-B9E2-7E999AB670F4Q24804759-39CBC9A2-325C-435D-BBA1-0B34ABAD1D2AQ33289120-7CBA5C48-AA7E-4E1D-9027-5F005A8DC60EQ33315604-779C178E-1D9B-4031-99F9-93938BA4A8D9Q33337445-F2266B51-9C32-48DC-BBDE-7FF641B7EBD2Q34123323-2D07CACC-CB5E-441F-90F3-718E823459DCQ34425230-0D4CAECD-E0CE-4F5A-BAF1-CBA98479AFF8Q34999979-37341447-4B4C-4E84-97B1-A0E9A9FE22D4Q35085782-B0915AEA-5AB5-4D32-AAC6-0AD606A7A5F8Q35605804-5B37366E-3B7B-4510-AAE0-74AE7A114A66Q35851488-BFCD6397-BA86-4C28-A394-44E9BCCF1898Q36458780-2B07F94C-591A-4606-B678-906D99188A51Q36856318-2A5EC73D-7ECE-41C5-B099-6F9000679AFCQ37021548-8435AEB9-3C18-4170-A621-7F43E8E07A53Q37117082-B920DA3E-5439-409E-9A3C-B74B6C4650A6Q37232123-344442A0-7806-4B9C-B922-5DB3612EC16EQ37539804-CC1E937B-D870-4505-B11E-1EE95429EA49Q37605747-6F17E42E-479E-4290-8804-96EF054C2F89Q37843728-7F7CA74A-DC7B-4F64-957D-17E60F8EA949Q37925127-B120D617-A178-4156-8193-B60824076BCCQ37931893-8E673622-BE19-4336-A5B4-11B9A71306C3Q38692509-88A5577C-AEEB-4C44-AC2B-740BA092F569Q39019991-7628F5EF-E3C1-46DA-B512-32AE4E9D0AD1Q41611182-440FFA82-DA91-4D95-8D18-8D9C7CDD087CQ41825111-73EC7E4B-E396-4A59-AA5B-A4868A0ACEC7Q42479799-5F57B4DF-DF91-48AC-BC0B-DBB5B07398AFQ42662678-CD21D4D8-8930-4973-A7C8-547481EBA0D1Q43635627-086CA836-C242-4299-8A99-25FC68748811Q43655387-17B25971-305C-4F0D-B4A9-69AE34ED0ECBQ45918155-2CD27C67-2AF9-4344-A334-7F7940DFFEACQ47559670-DD26E0EE-990F-4598-8250-CAB28497B32FQ54516899-B6180619-DB6E-4B8D-B205-CCA599528E82
P2860
Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Absence of methylation of CpG ...... in breast and ovarian cancers.
@ast
Absence of methylation of CpG ...... in breast and ovarian cancers.
@en
type
label
Absence of methylation of CpG ...... in breast and ovarian cancers.
@ast
Absence of methylation of CpG ...... in breast and ovarian cancers.
@en
prefLabel
Absence of methylation of CpG ...... in breast and ovarian cancers.
@ast
Absence of methylation of CpG ...... in breast and ovarian cancers.
@en
P2860
P356
P1476
Absence of methylation of CpG ...... in breast and ovarian cancers.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1997.526
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1013836365